Daniel Heller is a biomedical engineer and the head of the Cancer Nanotechnology Laboratory at the Sloan Kettering Institute. His research focuses on developing nanotechnologies aimed at advancing breakthroughs in the diagnosis and treatment of cancer and related diseases. Specifically, he works on drug delivery technologies that target therapies to specific disease sites, advanced diagnostics to detect various disease stages, and nanosensors that can accelerate the discovery of new therapies. His lab is at the forefront of innovation in molecular pharmacology, driven by an emphasis on improving patient care through targeted advancements in cancer treatment.